PhRMA Continues Critique of ICER Drug Pricing Studies

The Pharmaceutical Research and manufacturers of America (PhRMA) have repeatedly spoken out against the cost-effectiveness studies published by the Institute for Clinical and Economic Review (ICER) and has recently publicized its own four pointed list of recommendations to ICER. Read more here. (Source: Joe Cantlupe, BioPharma DIVE, 9/29/16)

You might also be interested in:

PAI and BresMed Join Forces to Support Expanded Use of More… July 22, 2019
Biomarkers and Companion diagnostics: Payer Insights September 26, 2019
Pharmerit Expands Market Access Support in Asia January 17, 2019
Review of Influence: The Institute for Clinical and Economic Review February 26, 2019
The Global Use of Medicine in 2019 and Outlook to 2023 January 29, 2019
Global Health Economics & Outcomes Research (HEOR) Services… October 23, 2019
Real-World Evidence and Value-Based Contracting – Swipe Left… February 27, 2019